# Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

> **NCT04509466** · PHASE1,PHASE2 · TERMINATED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 41 (actual)

## Conditions studied

- Extranodal NK/T-cell Lymphoma, Nasal Type

## Interventions

- **DRUG:** Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase
- **DRUG:** Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase
- **DRUG:** Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase

## Key facts

- **NCT ID:** NCT04509466
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-15
- **Primary completion:** 2022-01-30
- **Final completion:** 2022-01-30
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** The sponsor has adjusted its R\&D strategy.
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04509466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04509466, "Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04509466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*